RATHER

Rational Therapy for Breast Cancer: Individualized Treatment for Difficult-to-Treat Breast Cancer Subtypes

Coordinatore	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN    more  Organization address address: BELFIELD city: DUBLIN postcode: 4 contact info Titolo: Mr. Nome: Donal Cognome: Doolan Email: send email Telefono: +353 1 7161656 Fax: +353 1 7161216
Nazionalità Coordinatore	Ireland [IE]
Sito del progetto	http://www.ratherproject.com
Totale costo	7˙792˙107 €
EC contributo	5˙995˙786 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2010-two-stage
Funding Scheme	CP-FP
Anno di inizio	2011
Periodo (anno-mese-giorno)	2011-01-01   -   2016-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN  Organization address address: BELFIELD city: DUBLIN postcode: 4 contact info Titolo: Mr. Nome: Donal Cognome: Doolan Email: send email Telefono: +353 1 7161656 Fax: +353 1 7161216	IE (DUBLIN)	coordinator	921˙506.00
2	STICHTING HET NEDERLANDS KANKER INSTITUUT  Organization address address: PLESMANLAAN 121 city: AMSTERDAM postcode: 1066 CX contact info Titolo: Dr. Nome: Henri Cognome: Van Luenen Email: send email Telefono: +31 20 512 2097 Fax: +31 20 699 1383	NL (AMSTERDAM)	participant	1˙499˙587.50
3	OncoMark Limited  Organization address address: Weston Park 76 city: DUBLIN 14 postcode: - contact info Titolo: Dr. Nome: Mairin Cognome: Rafferty Email: send email Telefono: 35317163666 Fax: +353 1 716 3709	IE (DUBLIN 14)	participant	995˙520.00
4	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Mr. Nome: Keith Cognome: Cann Email: send email Telefono: +44 1223 333543 Fax: +44 1223 332988	UK (CAMBRIDGE)	participant	906˙227.44
5	Agendia BV  Organization address address: Science Park 406 city: Amsterdam postcode: 1098XH contact info Titolo: Dr. Nome: Iris Cognome: Simon Email: send email Telefono: +31 61 326 7875 Fax: +31 20 462 1505	NL (Amsterdam)	participant	786˙300.00
6	FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON  Organization address city: Barcelona postcode: 8035 contact info Titolo: Dr. Nome: Alejandro Cognome: Piris Gimenez Email: send email Telefono: +34 934893021 Fax: +34 934894212	ES (Barcelona)	participant	400˙645.12
7	INSTITUT CURIE  Organization address address: 26, rue d'Ulm city: PARIS postcode: 75248 contact info Titolo: Ms. Nome: Corinne Cognome: Cumin Email: send email Telefono: +33 1 56 24 66 22 Fax: +33 1 42 34 66 27	FR (PARIS)	participant	346˙000.00
8	LUNDS UNIVERSITET  Organization address address: Paradisgatan 5c city: LUND postcode: 22100 contact info Titolo: Dr. Nome: Karin Cognome: Jirström Email: send email Telefono: +46 40333088 Fax: +46 40 337063	SE (LUND)	participant	140˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs, with many mutations occurring in kinases or downstream signaling components. While there are several ongoing large-scale genome re-sequencing studies for the major cancer types, there is no systematic effort to investigate kinase mutations in distinct biological subtypes of these cancers. Here, we will explore the rate of activation of all kinases (the “kinome”) in two poor-prognosis subtypes of breast cancer for which there are currently no targeted therapies available, namely “triple negative” (TN) breast tumors lacking the estrogen-, progesterone- and HER2 receptors, constituting 15% of breast cancers, and invasive lobular carcinomas (ILC) of the breast, which represent 10% of breast tumors. Thus, we lack effective targeted therapies for one quarter of all breast cancer patients. In this project, we will identify and validate novel kinase targets for therapy for these TN and ILC subtypes. Kinase targets will be identified via a 4-pronged approach: i) direct re-sequencing of the kinome of 150 TN and 150 ILC tumors, ii) determination of abundance and activation status of kinases in these tumors by reverse phase protein array and tissue microarray technologies, iii) determination of copy number variation by SNP arrays, and iv) mRNA quantitation of the kinome using DNA microarrays. Potential kinase targets for therapy will be validated in preclinical models using RNA interference. Finally, we will perform a phase I/II clinical trial to test the efficacy of a selective PI3K inhibitor in breast cancer. The project will deliver proof-of-concept for novel therapeutic interventions, together with matched molecular diagnostic approaches for patient stratification, for up to 25% of breast cancer patients.'

Introduzione (Teaser)

Cancer genotyping has identified a number of correlations between mutations in specific genes and responses to targeted anti-cancer drugs. These cancer-specific mutations may lead to the design of more targeted and personalised treatment.